BACKGROUND: Non-pharmacological treatment programmes are being developed, in which specialised nurses take care of heart failure (HF) patients. Such disease management programmes might increase survival and quality of life in HF patients, but evidence on their cost-effectiveness remains limited. METHODS AND RESULTS: A prospective economic evaluation piggy-backed onto the randomised controlled Interdisciplinary Network for Heart Failure (INH) Study weighted costs of the intervention HeartNetCare -HF™ (HNC) regarding effectiveness, mortality and quality-adjusted life years (QALYs). To consider uncertainty sensitivity analyses were performed. Compared to usual care (UC), HNC revealed 8,284 <euro> per death avoided within the 6 month study follow-up period. The cost-utility analysis showed additional costs of 49,335 <euro> per QALY. CONCLUSION: Although HNC did not reduce short-term re-admission rates of HF patients hospitalised for cardiac decompensation within the first 180 days after discharge, HNC might reduce mortality and increase quality of life in these patients at reasonable costs. Therefore, long-term HNC-effects deserve further evaluation.
RCT Entities:
BACKGROUND: Non-pharmacological treatment programmes are being developed, in which specialised nurses take care of heart failure (HF) patients. Such disease management programmes might increase survival and quality of life in HF patients, but evidence on their cost-effectiveness remains limited. METHODS AND RESULTS: A prospective economic evaluation piggy-backed onto the randomised controlled Interdisciplinary Network for Heart Failure (INH) Study weighted costs of the intervention HeartNetCare -HF™ (HNC) regarding effectiveness, mortality and quality-adjusted life years (QALYs). To consider uncertainty sensitivity analyses were performed. Compared to usual care (UC), HNC revealed 8,284 <euro> per death avoided within the 6 month study follow-up period. The cost-utility analysis showed additional costs of 49,335 <euro> per QALY. CONCLUSION: Although HNC did not reduce short-term re-admission rates of HF patients hospitalised for cardiac decompensation within the first 180 days after discharge, HNC might reduce mortality and increase quality of life in these patients at reasonable costs. Therefore, long-term HNC-effects deserve further evaluation.
Authors: Christiane E Angermann; Stefan Störk; Götz Gelbrich; Hermann Faller; Roland Jahns; Stefan Frantz; Markus Loeffler; Georg Ertl Journal: Circ Heart Fail Date: 2011-09-28 Impact factor: 8.790
Authors: Carey Kimmelstiel; Daniel Levine; Kathleen Perry; Ayan R Patel; Ara Sadaniantz; Noreen Gorham; Margaret Cunnie; Lynne Duggan; Linda Cotter; Patricia Shea-Albright; Athena Poppas; Kenneth LaBresh; Daniel Forman; David Brill; William Rand; Douglas Gregory; James E Udelson; Beverly Lorell; Varda Konstam; Kathleen Furlong; Marvin A Konstam Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Alexander Göhler; Annette Conrads-Frank; Stewart S Worrell; Benjamin P Geisler; Elkan F Halpern; Rainer Dietz; Stefan D Anker; G Scott Gazelle; Uwe Siebert Journal: Eur J Heart Fail Date: 2008-08-28 Impact factor: 15.534
Authors: Scott D Solomon; Joanna Dobson; Stuart Pocock; Hicham Skali; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; James B Young; Eric L Michelson; Marc A Pfeffer Journal: Circulation Date: 2007-08-27 Impact factor: 29.690
Authors: Antonio López-Villegas; Daniel Catalán-Matamoros; Emilio Robles-Musso; Salvador Peiró Journal: Clin Res Cardiol Date: 2015-09-30 Impact factor: 5.460